Will allogeneic CAR T cells for CD19+ malignancies take autologous CAR T cells 'off the shelf'?

被引：31

作者：

DiNofia, Amanda M. ^{[1
,2
]}

Grupp, Stephan A. ^{[1
,2
]}

机构：

[1] Childrens Hosp Philadelphia, Cellular Therapy & Transplant Sect, Canc Immunotherapy Program, Philadelphia, PA 19104 USA

[2] Univ Penn, Dept Pediat, Div Oncol, Perelman Sch Med, Philadelphia, PA 19104 USA

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2021年 / 18卷 / 04期

关键词：

D O I：

10.1038/s41571-021-00485-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The question of whether allogeneic chimeric antigen receptor (CAR) T cells could replace autologous CAR T cell therapy has garnered considerable interest, but limited data have been available for comparisons to date. Now, Benjamin et al. have reported their experience with allogeneic anti-CD19 CAR T cells in 21 paediatric and adult patients with acute lymphoblastic leukaemia.

引用

页码：195 / 196

页数：2

共 50 条

[41] Autologous Anti-CD19 CAR T Cells as Therapy for Systemic Lupus Erythematosus
Radic, Marko
Randolph, Brion
TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (01): : 3 - 4
[42] Anti-CD19 CAR T-cells
Smith, Lan-Lan
LANCET ONCOLOGY, 2017, 18 (01): : 26 - 26
[43] Autologous CD19-Targeting CAR T Cells in a Patient With Refractory Juvenile Dermatomyositis
Nicolai, Rebecca
Merli, Pietro
Alvarez, Patricia Moran
Bracaglia, Claudia
Del Bufalo, Francesca
Marasco, Emiliano
Caiello, Ivan
Prencipe, Giusi
Algeri, Mattia
Cefalo, Maria G.
Becilli, Marco
Quintarelli, Concetta
Sinibaldi, Matilde
Hanssens, Linda
De Benedetti, Fabrizio
Locatelli, Franco
ARTHRITIS & RHEUMATOLOGY, 2024, 76 (10) : 1560 - 1565
[44] An "off-the-shelf" CD2 universal CAR-T therapy for T-cell malignancies
Xiang, Jingyu
Devenport, Jessica M.
Carter, Alun J.
Staser, Karl W.
Kim, Miriam Y.
O'Neal, Julie
Ritchey, Julie K.
Rettig, Michael P.
Gao, Feng
Rettig, Garrett
Turk, Rolf
Lee, Byung Ha
Cooper, Matthew L.
DiPersio, John F.
LEUKEMIA, 2023, 37 (12) : 2448 - 2456
[45] An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies
Jingyu Xiang
Jessica M. Devenport
Alun J. Carter
Karl W. Staser
Miriam Y. Kim
Julie O’ Neal
Julie K. Ritchey
Michael P. Rettig
Feng Gao
Garrett Rettig
Rolf Turk
Byung Ha Lee
Matthew L. Cooper
John F. DiPersio
Leukemia, 2023, 37 : 2448 - 2456
[46] Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells
Fang, Karen Kai-Lin
Lee, Jongbok
Khatri, Ismat
Na, Yoosu
Zhang, Li
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (09)
[47] Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells
Stefanie Koristka
Pauline Ziller-Walter
Ralf Bergmann
Claudia Arndt
Anja Feldmann
Alexandra Kegler
Marc Cartellieri
Armin Ehninger
Gerhard Ehninger
Martin Bornhäuser
Michael P. Bachmann
Cancer Immunology, Immunotherapy, 2019, 68 : 1401 - 1415
[48] Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells
Koristka, Stefanie
Ziller-Walter, Pauline
Bergmann, Ralf
Arndt, Claudia
Feldmann, Anja
Kegler, Alexandra
Cartellieri, Marc
Ehninger, Armin
Ehninger, Gerhard
Bornhaeuser, Martin
Bachmann, Michael P.
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (09) : 1401 - 1415
[49] Preclinical study of allogeneic CD19-CAR-DNT cells as an off-the-shelf immunotherapy drug for NHL
Yang, Liming
Wang, Dan
Xu, Shangzhi
Wang, Liuyang
Tong, Jianjun
Zhu, Honglin
Xu, Man
Li, Xiancai
Ji, Letu
Zheng, Chuntao
Xiang, Zhiqiang
Sun, Qinghua
Wang, Hengcai
CANCER RESEARCH, 2022, 82 (12)
[50] Functional demonstration of CD19 chimeric antigen receptor (CAR) engineered Epstein-Barr virus (EBV) specific T cells: An off-the-shelf, allogeneic CAR T-cell immunotherapy platform
Shen, Rhine R.
Pham, Christina D.
Wu, Michelle Min
Munson, Daniel J.
Aftab, Blake T.
CANCER RESEARCH, 2019, 79 (13)

← 1 2 3 4 5 →